Background:
Glioblastoma
(GBM)
is
the
most
common
primary
brain
malignant
tumor
and
one
of
lethal
human
cancers
with
very
limited
effective
therapeutics.
A
few
neoantigens
that
have
been
tested
in
trials
as
cancer
immunotherapeutic
vaccines
against
GBM
demonstrated
promising
but
ambiguous
results.
However,
there
no
systemic
exploration
neoantigen
landscape
its
related
microenvironment.Methods:
An
integrated
multi-omic
approach
consisting
WES,
RNA
sequencing,
bioinformatic
algorisms
was
applied
to
comprehensively
profile
mutation,
HLA
typing,
TCR/BCR
repertoire,
immune
cell
components
on
tissue
peripheral
blood
mononuclear
(PMBC)
specimen
24
patients.
The
characterized
a
cluster
peptides
designed
for
this
patient
cohort.Findings:
On
average,
148
mutated
genes
200
sites
per
were
identified,
predominant
cohort.
Diversified
genotypes
expression
rate
across
A,
B,
C
alleles,
A30:01&A11:01,
B13:02,
C06:02,
frequent
at
respective
alleles.
Clustered
CDR3
existed
decreased
richness
compared
PMBC.
NKT
Th1
cells
revealed
within
TMB.
Neoantigens
feasible
predicted
each
patient,
an
average
number
107.
Very
shared
by
more
than
two
patients
dominant
could
be
identified.
minimum
11-peptide
bulk
required
cover
24-patient
cohort,
guaranteeing
least
neoantigen.Interpretation:
Our
study
reveals
inherent
TME
heterogeneous
immunogenic
signatures,
which
should
facilitate
optimized
design
therapeutic
terms
target
selection
strategy.Funding:
This
received
support
from
Beijing
Municipal
Nature
Science
Foundation
(Grant
No.
Z191100007619018).Declaration
Interest:
authors
declare
competing
interests.Ethical
Approval:
All
provided
written
informed
consent
sample
collection
data
analyses.
approved
Ethical
Committee
Xuanwu
Hospital,
Beijing,
China.
Journal of Biomaterials Science Polymer Edition,
Год журнала:
2024,
Номер
35(13), С. 1978 - 1998
Опубликована: Июль 2, 2024
Glioma
cancer
is
the
primary
cause
of
cancer-related
fatalities
globally
for
both
men
and
women.
Traditional
chemotherapy
treatments
this
condition
frequently
result
in
reduced
efficacy
significant
adverse
effects.
This
investigation
developed
a
new
drug
delivery
system
chemotherapeutic
temozolomide
(TMZ)
using
pH-sensitive
zeolitic
imidazolate
frameworks
(ZIF-8).
These
nanoplatforms
demonstrate
excellent
biocompatibility
hold
potential
therapy.
Utilizing
favorable
reaction
milieu
offered
by
ZIFs,
'one-pot
method'
was
employed
fabrication
loading
drugs,
leading
to
good
capacity
loading.
TMZ@TA@ZIF-8
NPs
exhibit
notable
response
an
acidic
milieu,
resulting
enhanced
release
pattern
characterized
controlled
outcome.
The
effectiveness
inhibiting
migration
invasion
U251
glioma
cells,
as
well
promoting
apoptosis,
confirmed
through
various
tests,
including
MTT
(3-(4,5)-dimethylthiahiazo(-z-y1))
assay,
DAPI/PI
dual
staining,
cell
scratch
assay.
biochemical
fluorescent
staining
assays
showed
that
potentially
improved
ROS,
MMP,
triggered
apoptosis
cells.
In
cells
treated
with
NPs,
p53,
Bax,
Cyt-C,
caspase-3,
-8,
-9
expressions
were
significantly
enhanced,
while
Bcl-2
expression
diminished.
outcomes
show
therapeutic
agent
anti-glioma
properties.
Overall,
pH-responsive
systems
we
fabricated
great
treatment.
approach
has
make
contributions
improvement
therapy
overcoming
problems
associated
TMZ-based
treatments.
Cell Proliferation,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 24, 2024
Abstract
Chemodynamic
therapy
(CDT)
has
garnered
significant
attention
for
treating
diverse
malignant
tumours
due
to
its
minimally
invasive
nature,
reduced
damage
healthy
tissues,
and
potential
mitigation
of
side
effects.
However,
application
in
glioblastoma
(GBM)
is
hindered
by
the
diminished
capacity
CDT
agents
traverse
blood–brain
barrier
(BBB),
inadequate
tumour
targeting
efficiency,
restricted
availability
H
2
O
within
microenvironment
(TME).
To
address
these
challenges,
we
devised
a
novel
agent
(Fe@tFNAs‐ANG‐3AT)
based
on
tetrahedral
framework
nucleic
acids
(tFNAs).
Fe@tFNAs‐ANG‐3AT
was
constructed
anchoring
iron
ions
(Fe
3+
)
onto
dual
appendages‐modified
tFNAs.
Specifically,
one
appendage,
Angiopep‐2
(ANG,
penetrating
peptide),
facilitates
penetration
across
BBB
selective
cells.
Simultaneously,
second
3‐Amino‐1,2,4‐triazole
(3AT,
enzyme
inhibitor),
augments
levels
required
effective
treatment.
Upon
cell
internalization,
loaded
Fe
2+
overexpressed
glutathione
(GSH)
TME,
catalysing
generation
cytotoxic
hydroxyl
radicals
(·OH)
inducing
death
via
elevated
oxidative
stress
It
anticipated
that
holds
promise
as
transformative
treatment
strategy
GBM.
SAGE Open Medical Case Reports,
Год журнала:
2024,
Номер
12
Опубликована: Янв. 1, 2024
High-grade
gliomas
(HGGs)
are
the
most
aggressive
of
brain
tumors
and
one
common
primary
intracranial
malignancies.
The
poor
prognosis
after
treatment
HGGs
makes
these
a
challenge
to
treat
with
curative
intent.
Proton
radiation
therapy
is
recent
modality
that
being
explored
for
HGGs.
provides
improved
sparing
critical
normal
structures
while
giving
an
ablative
dose
tumor,
which
can
be
performed
more
accurately
than
photon
beam
therapy.
We
report
case
diffuse
HGG
treated
proton
radiotherapy
chemotherapy
previously
irradiation.
A
complete
radiographic
response
was
seen
on
MRI
imaging
Advances in molecular oncology,
Год журнала:
2024,
Номер
11(3), С. 68 - 78
Опубликована: Окт. 11, 2024
Introduction
.
Epidermal
growth
factor
receptor
(EGFR)
is
a
transmembrane
protein
of
the
tyrosine
kinase
family
that
activated
in
various
cancers
(non-small
cell
lung
cancer,
colorectal
head
and
neck
tumors).
In
glial
brain
tumors,
increased
EGFR
expression
levels
are
characteristic
most
aggressive
subtype,
glioblastoma.
Frequent
structural
changes
glioblastoma
amplification
chromosome
region
where
gene
located,
point
mutations,
as
well
deletion
exons
2–7
leading
to
formation
EGFRvIII
transcript.
Aim
To
determine
(point
mutations
gene,
transcript)
tumor
samples
using
different
methods
evaluate
their
potential
clinical
significance.
Materials
The
study
included
75
patients
with
gliomas
(70
them
glioblastoma)
aged
34
78
years
(mean
age
56
years).
DNA
RNA
isolation
was
performed
from
fresh
frozen
tissue,
peripheral
blood
leukocytes.
were
determined
by
next-generation
sequencing
(NGS),
β
allele
frequency
(BAF)
comparative
analysis
(normal-tumor)
copy
number
7
regions.
Quantitative
polymerase
chain
reaction
used
confirm
samples,
reverse
transcription-PCR
detect
variant.
Results
NGS
method
revealed
11/70
(16
%)
coding
regions
detected
26/70
(37
cases;
no
5
glioma
(astrocytoma,
oligodendroglioma).
All
cases
confirmed
quantitative
reaction.
search
for
transcript,
31
examined,
which
present
12
samples.
transcript
only
–
4/12
(33
%).
assess
significance
alterations,
occurrence
primary
recurrent
compared.
Conclusion
allows
both
gene.
associated
mutation
33
%
cases.
No
statistically
significant
differences
between
relapsed
glioblastomas
found.
Pilocytic
astrocytoma
(PA),
recognized
as
the
most
prevalent
central
nervous
system
(CNS)
tumor,
has
long
been
associated
with
calcifications,
a
characteristic
often
attributed
to
benign
or
indolent
growth
patterns.
In
this
study,
we
explored
calcified
attributes
in
these
tumors
that
beckon
deeper
understanding.
This
is
retrospective
on
set
of
seven
cases,
histopathological
diagnosis
pilocytic
calcifications
and
psammoma
bodies
(PB).
Despite
an
encouraging
overall
survival
outcome,
recurrence
four
cases
cast
some
doubt
conventional
classification.
The
histological
study
revealed
spectrum
varying
size
morphology,
all
which
exhibited
positive
reactivity
glial
fibrillary
acidic
protein
(GFAP),
osteoconduction,
osteopontin.
Notably,
immunohistochemistry
showed
hyaline
displaying
atypical
immune
profile,
strikingly
negative
for
vimentin
GFAP,
robust
positivity
epidermal
factor
receptors
(EGFR),
tumor
necrosis
factor-alpha
(TNF-α),
interleukin
1
beta
(IL-1β).
These
results
stimulated
speculation
identity
may
have
extended
potentially
embraced
realm
calcifying
pseudoneoplasms
neuraxis
(CAPNON),
underscored
by
intense
pilot
gliosis.
transcends
mere
anatomical
exploration;
it
delves
into
intricacies
tumors,
casting
spotlight
dynamic
interplay
between
PA
CAPNON.
As
traverse
frontiers
neuro-oncology,
findings
pave
way
innovative
avenues
diagnostics
therapeutics
tumors.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Май 6, 2024
Abstract
Glioblastoma
Multiforme
(GBM)
is
a
highly
aggressive
and
lethal
form
of
brain
tumor,
presenting
significant
challenges
in
treatment
management.
In
this
study,
we
propose
advanced
control
models
for
the
management
GBM,
focusing
on
optimization
drug
therapies
adaptive
regulation
tumor
volume.
Leveraging
fractional-order
mathematical
modeling,
our
approach
integrates
modeling
techniques
with
theory
to
develop
comprehensive
strategies
GBM
The
proposed
aim
optimize
by
dynamically
adjusting
parameters
based
real-time
volume
monitoring.
This
allows
personalized
regimens
tailored
specific
characteristics
enhancing
therapeutic
efficacy
while
minimizing
adverse
effects.
By
harnessing
capabilities
research
provides
novel
framework
advancing
offering
new
insights
combating
formidable
disease
MSC
Classification:
92C55,
93C95,
92B05,
35R11,
35A22,
92C50,
35Q53,
49N90.
